← IRTC
IRTC— iRhythm Holdings, Inc.
Health CareSurgical & Medical Instruments & Apparatus
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue, net | $747.1M+26.2% | $591.8M+20.1% | $492.7M+19.9% | $410.9M+27.3% | $322.8M+21.7% | $265.2M+23.6% | $214.6M+45.7% | $147.3M+48.6% | $99.1M |
| Cost of revenue | $219.9M+19.3% | $184.3M+14.6% | $160.9M+24.4% | $129.3M+18.3% | $109.3M+55.5% | $70.3M+33.9% | $52.5M+35.3% | $38.8M+37.6% | $28.2M |
| Gross profit | $527.3M+29.4% | $407.5M+22.8% | $331.8M+17.8% | $281.6M+31.9% | $213.6M+9.6% | $194.9M+20.3% | $162.1M+49.4% | $108.5M+53.0% | $70.9M |
| Research and development | $84.6M+18.4% | $71.5M+18.6% | $60.2M+29.3% | $46.6M+20.5% | $38.7M-6.4% | $41.3M+10.8% | $37.3M+78.8% | $20.9M+57.3% | $13.3M |
| Acquired in-process research and development | $3.0M-90.6% | $32.4M | $0 | $0 | — | — | — | — | — |
| Selling, general and administrative | $492.6M+17.7% | $418.6M+8.5% | $385.6M+19.7% | $322.2M+17.2% | $274.8M+39.3% | $197.2M+9.9% | $179.5M+34.7% | $133.3M+56.4% | $85.3M |
| Impairment charges | $4.5M+595.5% | $641K-94.2% | $11.1M | — | — | — | — | — | — |
| Total operating expenses | $584.7M+11.8% | $523.0M+14.5% | $457.0M+15.6% | $395.4M+26.1% | $313.5M+31.4% | $238.6M+10.0% | $216.8M+40.6% | $154.2M+56.5% | $98.5M |
| Loss from operations | -$57.4M+50.3% | -$115.5M+7.7% | -$125.2M-10.0% | -$113.8M-13.8% | -$99.9M-128.8% | -$43.7M+20.2% | -$54.8M-19.8% | -$45.7M-65.6% | -$27.6M |
| Interest income | $21.5M-1.9% | $21.9M+245.3% | $6.4M+170.3% | $2.4M | — | — | — | — | — |
| Interest expense | -$13.2M-2.6% | -$12.8M-251.3% | -$3.6M+11.8% | -$4.1M-254.0% | -$1.2M+23.0% | -$1.5M+7.5% | -$1.6M+47.3% | -$3.1M+8.0% | -$3.4M |
| Loss on extinguishment of debt | $0+100.0% | -$7.6M | $0 | $0 | — | — | — | -$3.0M | $0 |
| Other income (expense), net | $5.4M+334.3% | $1.3M+732.8% | -$198K+36.9% | -$314K-366.1% | $118K-92.6% | $1.6M-16.0% | $1.9M+26.2% | $1.5M+21.3% | $1.2M |
| Total interest and other income (expense), net | $13.8M+396.5% | $2.8M+11.0% | $2.5M+219.2% | -$2.1M | — | — | — | — | — |
| Loss before income taxes | -$43.6M+61.3% | -$112.7M+8.1% | -$122.7M-5.8% | -$115.9M-14.7% | -$101.0M-131.6% | -$43.6M+20.0% | -$54.5M-8.3% | -$50.3M-69.2% | -$29.7M |
| Income tax provision | $953K+68.7% | $565K-24.7% | $750K+178.8% | $269K-26.7% | $367K+60.3% | $229K+252.3% | $65K+47.7% | $44K | $0 |
| Net loss | -$44.6M+60.7% | -$113.3M+8.2% | -$123.4M-6.2% | -$116.2M-14.6% | -$101.4M-131.3% | -$43.8M+19.7% | -$54.6M-8.3% | -$50.4M-69.4% | -$29.7M |
| Net loss per common share, basic (in USD per share) | -$1K+61.7% | -$4K+10.1% | -$4K-4.1% | -$4K-12.1% | -$3K-119.0% | -$2K+26.9% | -$2K | — | — |
| Net loss per common share, diluted (in USD per share) | -$1K+61.7% | -$4K+10.1% | -$4K-4.1% | -$4K-12.1% | -$3K-119.0% | -$2K+26.9% | -$2K | — | — |
| Weighted-average shares, basic (in shares) | $32.0M+2.6% | $31.2M+2.2% | $30.5M+2.0% | $29.9M+2.0% | $29.3M-99.9% | $27.75B+9.8% | $25.27B | — | — |
| Weighted-average shares, diluted (in shares) | $32.0M+2.6% | $31.2M+2.2% | $30.5M+2.0% | $29.9M+2.0% | $29.3M-99.9% | $27.75B+9.8% | $25.27B | — | — |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Source: SEC EDGAR 10-K and 10-Q filings. Up to 10 years annual / 16 quarters shown.